J Cancer 2020; 11(17):5150-5161. doi:10.7150/jca.39467

Research Paper

Prognostic role of ACTL10 in Cytogenetic Normal Acute Myeloid Leukemia

Rui Lai1*, Weilong Zhang2*, Xue He3*, Xinhui Liao4, Xiaoni Liu4, Wei Fu5, Ping Yang2, Jing Wang2, Kai Hu2, Xiaoliang Yuan4, Xiuru Zhang3✉, Hongmei Jing2✉, Weiyou Liu4✉

1. Department of the Respiratory medicine, The People's Hospital of Ruijin City, Ruijin, 342500, China.
2. Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China.
3. Department of Pathology, Beijing Tiantan Hospital Affiliated with Capital Medical University, No. 6 Tiantan Xili, Beijing, 100050, China.
4. Department of Respiratory medicine, First Affiliated Hospital Gannan Medical University, Ganzhou, 341000, China.
5. Peking University Third Hospital, Beijing, 100191, China.
*These authors contributed equally to this work.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Lai R, Zhang W, He X, Liao X, Liu X, Fu W, Yang P, Wang J, Hu K, Yuan X, Zhang X, Jing H, Liu W. Prognostic role of ACTL10 in Cytogenetic Normal Acute Myeloid Leukemia. J Cancer 2020; 11(17):5150-5161. doi:10.7150/jca.39467. Available from https://www.jcancer.org/v11p5150.htm

File import instruction

Abstract

ACTL10 is a member of the actin family; however, despite previous studies suggesting that certain proteins in this family may be related to the pathogenesis of leukemia, to the best of our knowledge, no studies to date have demonstrated any association between ACTAL10 and leukemia. Thus, the present study aimed to determine the association between ACTL10 expression levels, DNA methylation levels and the clinical prognosis in cytogenic normal acute myeloid leukemia (CN-AML). Data from seventy-five patients with CN-AML and patients with AML treated with chemotherapy or allogeneic hematopoietic stem cell transplantation were obtained from The Cancer Genome Atlas (TCGA) dataset and were used to analyze the clinical prognosis of ACTL10 RNA expression levels and DNA methylation levels. In addition, the study also investigated the combined clinical prognosis of ACTL10 RNA expression levels and ACTL10 DNA methylation levels in 74 patients with CN-AML from the TCGA dataset. ACTL10 RNA expression levels were observed to be highly expressed in patients with CD34+/CD38+ AML (P<0.01). Both ACTL10 RNA expression levels and DNA methylation were found to be independent prognostic factors for patients with CN-AML; patients with CN-AML in the ACTL10 RNA-high expression group had an increased EFS (P=0.0016) and OS (P=0.014) and patients in ACTL10 DNA methylation-low group also demonstrated a long EFS (P<0.0001) and OS (P=0.004). Notably, integrating ACTL10 RNA expression levels and ACTL10 DNA methylation levels could more accurately predict the prognosis of patients with CN-AML (EFS and OS, P<0.0001). In conclusion, the findings of the present study suggested that the high RNA expression levels and low DNA methylation levels of ACTL10 may predict a good prognosis in patients with CN-AML.

Keywords: ACTL10, CN-AML, RNA expression, DNA methylation